Our vision is a future where drugs are developed without the use of animals, where doctors know how a patient will react to a drug before prescribing it, and where lifesaving transplant organs are created, not harvested.
Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. Our company is built on over 10 years of research and development and formed through a collaboration between world-class research groups in Engineering and Medicine at the University of British Columbia. Our proprietary Lab-on- a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. We are focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate drug discovery and development, and enable the creation of cutting-edge tissue therapies of the future.
An entrepreneur, engineer, inventor, Tamer currently serves as our President and Chief Executive Officer.
Konrad is the Chief Technology Officer at Aspect and is responsible for our technology and intellectual property development.
Sam is the Chief Scientific Officer at Aspect and is responsible for our scientific innovation and development.